Table 2.
BOLT trial overview
| Patient characteristics | 200 mg (n=79) | 800 mg (n=151) |
|---|---|---|
| Age, years | 67 (23–92) | 65 (24–93) |
| Sex, n (%) | ||
| Female | 31 (39) | 55 (36) |
| Male | 48 (61) | 96 (64) |
| Metastases, n (%) | 14 (18) | 23 (15) |
| Lung | 10 (71) | 12 (52) |
| Lymph nodes | 1 (7) | 7 (30) |
| Bone | 2 (14) | 5 (22) |
| Other | 3 (21) | 7 (30) |
Note: Adapted from The Lancet, Vol 16 edition (6) Migden, MR, Guminski A, Gutzmer, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Pages No., 716–728, Copyright (2015), with permission from Elsevier.55
Abbreviation: BOLT, Basal cell carcinoma Outcomes in LDE225 Treatment.